AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30277538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 30277538 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 0
Study 30277538 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0
Study 30277538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0
Study 30277538 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 0
Study 30277538 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 0
Study 30277538 — intervention group
Group type: COMPARATOR
Intervention: Asinercept (APG101)
Number of subjects: 0
Study 30277538 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study 29472198 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) initiated at birth or 1 hour after birth in combination with standard thermoregulation care
Number of subjects: 0
Study 29472198 — intervention group
Group type: COMPARATOR
Intervention: Standard thermoregulation care
Number of subjects: 0
Study 27017366 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus- and probucol-eluting stents
Number of subjects: 3002
Study 27017366 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 3002
Study 24732098 — intervention group
Group type: EXPERIMENTAL
Intervention: VR ACLS training with comprehensive feedback components
Number of subjects: 148
Study 24732098 — intervention group
Group type: EXPERIMENTAL
Intervention: VR ACLS training with limited feedback components
Number of subjects: 148
Study 24732098 — intervention group
Group type: COMPARATOR
Intervention: Traditional ACLS training (Control)
Number of subjects: 148
Study 22070666 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Number of subjects: 20
Study 22070666 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy only (Control)
Number of subjects: 20
Study 18082510 — intervention group
Group type: EXPERIMENTAL
Intervention: High alpha-linolenic acid (ALA) diet
Number of subjects: 0
Study 18082510 — intervention group
Group type: COMPARATOR
Intervention: Low alpha-linolenic acid (ALA) group (control)
Number of subjects: 0
Study 18082510 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine ethanol consumption
Number of subjects: 0
Study 16209900 — intervention group
Group type: EXPERIMENTAL
Intervention: Females during early deceleration
Number of subjects: 30
Study 14514169 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical knowledge databases (DIMDI, OVID CD-ROM)
Number of subjects: 0
Study 10772053 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics (CM) prosthesis
Number of subjects: 200
Study 10772053 — intervention group
Group type: COMPARATOR
Intervention: Monostrut (M) prosthesis
Number of subjects: 200
Study 8325279 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg/day for a minimum of 7 days before a second iomazenil study (Group 1, n = 7)
Number of subjects: 14
Study 8325279 — intervention group
Group type: COMPARATOR
Intervention: No clobazam (Group 2, n = 4)
Number of subjects: 14
Study 3524843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 150 mg/day
Number of subjects: 182
Study 3524843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 29497960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 55
Study 29497960 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 55
Study 26971164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption (HA) with CytoSorb® during cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 26971164 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB without HA
Number of subjects: 40
Study 26971164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption (HA) with CytoSorb®
Number of subjects: 40
Study 23860416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (supervised walking or stationary cycling 3 days/week for 12 weeks, plus 2 days/week home exercise after 18 supervised sessions)
Number of subjects: 1870
Study 23860416 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care without exercise training)
Number of subjects: 1870
Study 22890119 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 286
Study 22890119 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 286
Study 19908060 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) bout 1
Number of subjects: 9
Study 19908060 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) bout 2
Number of subjects: 9
Study 18771879 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 151
Study 18771879 — intervention group
Group type: COMPARATOR
Intervention: Supervised hospital-based exercise
Number of subjects: 151
Study 16482467 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group (n=47)
Number of subjects: 103
Study 16482467 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=56)
Number of subjects: 103
Study 12952269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (add-on therapy)
Number of subjects: 20
Study 10998773 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation (MH)
Number of subjects: 100
Study 10998773 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐MH group)
Number of subjects: 100
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole q.d. for 28 days plus 750 mg amoxicillin b.i.d. for the first 10 days (omep-20-amox group, N = 22)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.i.d. for 28 days plus 750 mg amoxicillin b.i.d. for the first 10 days (omep-40-amox group, N = 22)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg bismuth subsalicylate q.i.d. for 28 days, and 750 mg amoxicillin b.i.d., 500mg metronidazole t.i.d. for the first 7 days (triple therapy group, N = 25)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole q.d. for 28 days (omep-20 group, N = 22)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine b.i.d. or 400 mg cimetidine b.i.d. for 28 days (H2-antagonist group, N = 21)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy group (N = 25)
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: Omep-20-amox, omep-40-amox, triple therapy, omep-20 groups
Number of subjects: 112
Study 8935224 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 antagonist group
Number of subjects: 112
Study 1526418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid enema (1 g daily for 2 weeks)
Number of subjects: 199
Study 1526418 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate foam (90 mg daily for 2 weeks)
Number of subjects: 199
Study 3885626 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (50 Gy)
Number of subjects: 0
Study 3885626 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation + postoperative saturation (25 Gy)
Number of subjects: 0
Study 3885626 — intervention group
Group type: COMPARATOR
Intervention: Preoperative irradiation alone (25 Gy)
Number of subjects: 0
Study 29486867 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 73
Study 29486867 — intervention group
Group type: COMPARATOR
Intervention: Monitored attention control
Number of subjects: 73
Study 28724423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered short-term cognitive-behavioural therapy (T-CBT)
Number of subjects: 216
Study 28724423 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 216
Study 26151135 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 2.5 g/day
Number of subjects: 21
Study 26151135 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 5.0 g/day
Number of subjects: 21
Study 26151135 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 7.5 g/day
Number of subjects: 21
Study 24140940 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique with extensive manipulation (GROUP A)
Number of subjects: 90
Study 24140940 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique with minimal manipulation (GROUP B)
Number of subjects: 90
Study 24140940 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic technique (GROUP C)
Number of subjects: 90
Study 21059701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 0
Study 21059701 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (NS)
Number of subjects: 0
Study 18356657 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-cardiopulmonary bypass (CPB)
Number of subjects: 98
Study 16440364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 276
Study 16440364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 16440364 — intervention group
Group type: EXPERIMENTAL
Intervention: YMDD mutant HBV
Number of subjects: 276
Study 16440364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-YMDD mutant HBV
Number of subjects: 276
Study 16440364 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 276
Study 12580664 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxing trials at various tempos (60, 72, 84, 96, 108, and 120 b.min(‐1))
Number of subjects: 18
Study 11100345 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of absolute alcohol (n = 44)
Number of subjects: 208
Study 11100345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation (BICAP; n = 42)
Number of subjects: 208
Study 11100345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser (n = 40)
Number of subjects: 208
Study 11100345 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of absolute ethanol + octreotide (n = 42)
Number of subjects: 208
Study 11100345 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of absolute ethanol + omeprazole (n = 40)
Number of subjects: 208
Study 9345156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextraction orthodontic treatment
Number of subjects: 35
Study 9345156 — intervention group
Group type: COMPARATOR
Intervention: Extraction orthodontic treatment
Number of subjects: 35
Study 8462205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 6 mg/kg body weight
Number of subjects: 0
Study 8462205 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin treatment
Number of subjects: 0
Study 3756057 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (M) 0.2 mg kg‐1 i.v. and dihydralazine (DH) 0.2 mg kg‐1 i.v.
Number of subjects: 51
Study 3756057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (DH) 0.2 mg kg‐1 i.v. alone
Number of subjects: 51
Study 3756057 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 51
Study 29776872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby
Number of subjects: 106
Study 29776872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose
Number of subjects: 106
Study 29776872 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study 28487001 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS nonpayment policy implementation
Number of subjects: 0
Study 28487001 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-Medicare patients)
Number of subjects: 0
Study 28487001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Medicare population to control group
Number of subjects: 0
Study 25987694 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular weight heparin)
Number of subjects: 312
Study 25987694 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (observation group)
Number of subjects: 312
Study 23339958 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1028
Study 23339958 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1028
Study 23339958 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin vs Aspirin
Number of subjects: 1028
Study 20717848 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nasal CPAP
Number of subjects: 17
Study 20717848 — intervention group
Group type: COMPARATOR
Intervention: Sham nasal CPAP
Number of subjects: 17
Study 19021919 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy reduced-salt Japanese diet (dietary score 3)
Number of subjects: 9086
Study 19021919 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy reduced-salt Japanese diet (dietary score 4-7)
Number of subjects: 9086
Study 19021919 — intervention group
Group type: COMPARATOR
Intervention: Dietary score group 0-2 (reference group)
Number of subjects: 9086
Study 17512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amitriptyline 25 mg
Number of subjects: 10
Study 17512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amitriptyline 50 mg
Number of subjects: 10
Study 17512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amitriptyline 100 mg
Number of subjects: 10
Study 15152535 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal naproxen
Number of subjects: 40
Study 15152535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11216935 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV seroconversion
Number of subjects: 290
Study 9772850 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention targeting aggressive/disruptive behavior
Number of subjects: 2311
Study 9772850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2311
Study 8170427 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mailing campaign and pharmacist visit
Number of subjects: 182
Study 8170427 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (Control)
Number of subjects: 182
Study 2453226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 0
Study 2453226 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral administration
Number of subjects: 0
Study 2453226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration
Number of subjects: 0
Study 31124396 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage least squares estimation using cluster-level summaries
Number of subjects: 0
Study 31124396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for baseline covariates
Number of subjects: 0
Study 31124396 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate degrees of freedom correction for inference
Number of subjects: 0
Study 31124396 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations of two-stage least squares
Number of subjects: 0
Study 30019241 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injected in the early postoperative period
Number of subjects: 19
Study 30019241 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 19
Study 28045276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating facial feature similarity prior to making same/different identity decisions to pairs of face images
Number of subjects: 0
Study 28045276 — intervention group
Group type: COMPARATOR
Intervention: Rating similarity of personality traits and image quality parameters
Number of subjects: 0
Study 28045276 — intervention group
Group type: COMPARATOR
Intervention: Comparison of trained forensic facial image examiners
Number of subjects: 0
Study 28045276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregating feature ratings of multiple examiners
Number of subjects: 0
Study 26169675 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 21
Study 26169675 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 21
Study 23985411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (started 2 weeks before surgery and continued postoperatively at 0.5 mg/kg, increased to a maximum of 2 mg/kg)
Number of subjects: 101
Study 23985411 — intervention group
Group type: COMPARATOR
Intervention: Control group (sildenafil started only postoperatively at 0.5 mg/kg, increased to a maximum of 2 mg/kg)
Number of subjects: 101
Study 23985411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil group
Number of subjects: 101
Study 23985411 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 23985411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 21218289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 23
Study 21218289 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep control
Number of subjects: 23
Study 18439313 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐kernel wheat bread with vinegar
Number of subjects: 15
Study 18439313 — intervention group
Group type: COMPARATOR
Intervention: Wholemeal wheat bread
Number of subjects: 15
Study 18439313 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread with vinegar
Number of subjects: 15
Study 18439313 — intervention group
Group type: COMPARATOR
Intervention: Reference meal (white wheat bread without vinegar)
Number of subjects: 15
Study 16503536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 20 mg 3 times daily for 8 weeks
Number of subjects: 119
Study 16503536 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (Control group A)
Number of subjects: 119
Study 14550702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating gel-based insoles
Number of subjects: 27
Study 10902887 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam cushions (50, 70, 100, 120 mm thick)
Number of subjects: 32
Study 10902887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushions with lower stiffness
Number of subjects: 32
Study 10902887 — intervention group
Group type: COMPARATOR
Intervention: Rigid wooden seat
Number of subjects: 32
Study 8936659 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (octreotide 200 micrograms q8h subcutaneously)
Number of subjects: 18
Study 8936659 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (prednisone 1 mg/kg/day in decreasing doses)
Number of subjects: 18
Study 8936659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Somatostatin and Corticosteroid)
Number of subjects: 18
Study 1543852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator exhaust capnography
Number of subjects: 40
Study 6388810 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservation surgery and irradiation
Number of subjects: 1073
Study 6388810 — intervention group
Group type: COMPARATOR
Intervention: Radical or modified radical mastectomy
Number of subjects: 1073
Study 6388810 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for first breast cancer
Number of subjects: 1073
Study 31094074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg
Number of subjects: 108
Study 31094074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 29548848 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (200 mg/day) for 26 weeks
Number of subjects: 60
Study 29548848 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 60
Study 27144849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg daily)
Number of subjects: 1922
Study 27144849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1922
Study 25209956 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal exercise outcome condition (experienced during or directly following an exercise bout)
Number of subjects: 135
Study 25209956 — intervention group
Group type: COMPARATOR
Intervention: Distal exercise outcome condition (experienced after days, months, or years of regular exercise)
Number of subjects: 135
Study 20629075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg/24 hr
Number of subjects: 505
Study 20629075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 hr
Number of subjects: 505
Study 20629075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 15546135 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose melphalan (180 mg/m²) with autologous bone marrow support
Number of subjects: 167
Study 15546135 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 167
Study 11674981 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 motor responses located (Group A)
Number of subjects: 100
Study 11674981 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 motor responses located (Group B)
Number of subjects: 100
Study 11674981 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 motor responses located (Group C)
Number of subjects: 100
Study 11674981 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 non-musculocutaneous responses located (Group D)
Number of subjects: 100
Study 11674981 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 non-musculocutaneous response located (Group E)
Number of subjects: 100
Study 10420071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 1 mg/kg body weight
Number of subjects: 5
Study 10420071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LMWH-adjusted dose plus UFH 2,500 IU fix dose (ComHep)
Number of subjects: 5
Study 10420071 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH 2,500 IU/10 kg body weight (UFHvar)
Number of subjects: 5
Study 10420071 — intervention group
Group type: COMPARATOR
Intervention: UFH 2,500 IU fix dose (FixUFH)
Number of subjects: 5
Study 8048850 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-quarter Nissen fundoplication with dissection and exclusion of vagus nerves
Number of subjects: 42